ArticleAnnals of laboratory medicine2024
Changing Genotypic Distribution, Antimicrobial Susceptibilities, and Risk Factors of Urinary Tract Infection Caused by Carbapenemase-Producing
Article in Annals of laboratory medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Prevalence of colistin resistance in clinical isolates ofFrontiers in microbiology · 2024Pooled it
- Article
- Antimicrobial Resistance Profiles ofPolish journal of microbiology · 2025Article
- Epidemiology and risk factors of healthcare-associated urinary tract infections: a prospective study in a Tunisian tertiary hospital.Scientific reports · 2025Article
- Pseudomonas aeruginosa clinical isolates in Egypt: phenotypic, genotypic, and antibiofilm assessment of Pluronic F-127.BMC microbiology · 2025Article
- Epidemiology of urinary tract infections in the Middle East and North Africa, 1990-2021.Tropical medicine and health · 2025Article
- Risk Factors for Development and Mortality of Carbapenem-ResistantInfection and drug resistance · 2025Article
- Importance of the Molecular Epidemiological Monitoring of Carbapenem-ResistantAnnals of laboratory medicine · 2024Article
- Challenges of Carbapenem-resistantAnnals of laboratory medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Methods: In total, 1,652 non-duplicated Results: The prevalence of carbapenem-non-susceptible Conclusions: The changing trend and genetic distribution of CPPA isolates emphasize the need for relentless monitoring to control further dissemination. The use of carbapenems, ICU stay, and WBC count should be considered risk factors, and aggressive antibiotic stewardship programs and monitoring may serve to prevent worse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.